OBFC2A Antibody - #DF12433

Fig. 5 NABP1 is a direct target of ZC3H13. (A) Venn diagrams show 1347 upregulated m6A modification mRNAs from GSE165100, 2223 upregulated genes from GSE153625, and 2745 upregulated genes from GSE142137; and the expressions of the 3 genes selected through the intersection of datasets. (B) Representative images of NABP1 IHC staining in kidney biopsies from AKI patients. (C) Western blotting analysis of NABP1 in AKI mice. (D-E) qPCR (D) and Western blotting (E) showed the induction of NABP1 by 10 µmol/L cisplatin for indicated hours in HK2 cells (n = 3). (F) Alterations in NABP1 m6A modifications in HK2 cells with or without cisplatin as determined by MeRIP-qPCR (n = 3). (G) The structures of the luciferase reporters. (H) The relative luciferase activity of WT group, CDS-mutant group, and 3’UTR-mutant group in the presence of cisplatin (n = 3). (I-K) NABP1 expression in HK2 cells exposed to cisplatin with ZC3H13 knockdown, as measured by qPCR (I; n = 3), Western blotting (J), and immunofluorescent staining (K). (L) Alterations in NABP1 m6A modification in HK2 cells with or without ZC3H13 knockdown as determined by MeRIP-qPCR (n = 3). (M) Alterations in NABP1 m6A modification in HK2 cells with or without ZC3H13 overexpression as determined by MeRIP-qPCR (n = 3). (N) Western blotting analysis of NABP1 in AKI mice with ZC3H13 knockdown. Data are showed as means ± SD. *P